For example, the range of reported CLDN3 positive cases ranged from 25 to 73.6% in gastric cancer [20, 21], from 32 to 95% in breast cancer of no special type [26, 27], and from 41.4 to 97.0% in pulmonary adenocarcinoma [28, 29]. The gene discussed is CLDN3; the disease is gastric cancer.